Zacks Investment Research on MSN
Medifast's Q3 Loss Wider Than Expected, Sales Decline 36% Y/Y
Medifast, Inc. (MED) delivered third-quarter 2025 results, with the top line surpassing the Zacks Consensus Estimate while ...
In a recent study published in the New England Journal of Medicine, an international team of researchers evaluated the efficacy and safety of once-daily oral orforglipron versus placebo over 72 weeks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback